Brendan David Stamper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brendan David Stamper has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Sigrid C. Roberts
School of Pharmacy, Pacific University, Hillsboro, OR 97123, USA
3 shared publications - Catherine Marlow
School of Pharmacy, Pacific University Oregon, 222 SE 8th Ave, Ste 451, Hillsboro, OR 97123, USA
2 shared publications - Fawzy Elbarbry
School of Pharmacy, Pacific University, Hillsboro, OR, USA
2 shared publications - John P. Harrelson
Pacific Univ School of Pharmacy
2 shared publications - Ngoc Uy Nguyen
Pacific University School of Pharmacy, 222 S.E. 8th Avenue #451, Hillsboro, OR 97123, USA
2 shared publications Sidney D. Nelson
Departments of Medicinal Chemistry and Environmental and Occupational Health Sciences, University of Washington, Seattle, USA
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1923146
Mapping the antileishmanial structure-activity relationship of eugenol
Leishmaniasis is a neglected tropical disease with a devastating global impact. The current medications on the market for treating this protozoan parasitic infection are insufficient to fit the global need, with long durations of therapy, growing resistance rates, and severe adverse effects. This investigation aims to characterize an antileishmanial structure-activity relationship for the natural product eugenol. With Leishmania donovani as a model, a series of dose-response curves were performed against eugenol and several of its structural analogs. The same set of compounds was tested against the human monocyte cell THP-1 to characterize their selective toxicity. Subsequently, the pharmacokinetic parameters of the tested compounds were estimated using the in silico modelling software, Percepta®. Eugenol and its analogs demonstrated varying levels of antileishmanial potency, with 4-allylphenol (chavicol) as the most potent compound tested and with the most promising selectivity index. In comparing the potencies and structures of the compounds tested, the data suggests that the para-substituted allyl tail and the phenolic group are important to conferring potency, while the ortho-methoxy substitutions decreased potency. Furthermore, the pharmacokinetic properties of these compounds were predicted to closely resemble eugenol with little risk of cytochrome P450 (CYP) interactions. While more testing is needed to confirm the mechanisms and safety of these compounds, these results suggest eugenol analogs show promise as future antileishmanial therapies.
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1923146
Open AccessMapping the antileishmanial structure-activity relationship of eugenol
Leishmaniasis is a neglected tropical disease with a devastating global impact. The current medications on the market for treating this protozoan parasitic infection are insufficient to fit the global need, with long durations of therapy, growing resistance rates, and severe adverse effects. This investigation aims to characterize an antileishmanial structure-activity relationship for the natural product eugenol. With Leishmania donovani as a model, a series of dose-response curves were performed against eugenol and several of its structural analogs. The same set of compounds was tested against the human monocyte cell THP-1 to characterize their selective toxicity. Subsequently, the pharmacokinetic parameters of the tested compounds were estimated using the in silico modelling software, Percepta®. Eugenol and its analogs demonstrated varying levels of antileishmanial potency, with 4-allylphenol (chavicol) as the most potent compound tested and with the most promising selectivity index. In comparing the potencies and structures of the compounds tested, the data suggests that the para-substituted allyl tail and the phenolic group are important to conferring potency, while the ortho-methoxy substitutions decreased potency. Furthermore, the pharmacokinetic properties of these compounds were predicted to closely resemble eugenol with little risk of cytochrome P450 (CYP) interactions. While more testing is needed to confirm the mechanisms and safety of these compounds, these results suggest eugenol analogs show promise as future antileishmanial therapies.
- 23 May 2026
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 18 (9) , 102689
Design and implementation of the extended 5-year doctor of pharmacy degree pathway
- 23 May 2026
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 18 (9) , 102689
Design and implementation of the extended 5-year doctor of pharmacy degree pathway
- 27 November 2025
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 36 (2) , 241-249
Cross-dataset transcriptomic pathway ranking highlights MAPK signaling in diquat-induced hepatocellular toxicity
Diquat is used in agriculture as an herbicide but poses significant health risks upon exposure. Current treatment for toxic exposures to diquat focuses on supportive care, and there is a need for better understanding of the molecular mechanisms underlying diquat-induced injury in order to develop more targeted antidotes. To this end, TAMH cells were exposed to various concentrations of diquat to determine toxicologically relevant concentrations followed by subsequent transcriptomic analysis. Data mining from the MAQC-II dataset, which was accessed through the Gene Expression Omnibus (GEO) was also leveraged during the gene network analysis. A median lethal concentration (LC50) for diquat in the TAMH line was determined to be 18 μM, with significant cell death observed at 9 hours. Microarray data identified 3,578 significantly altered transcripts in the TAMH model and 6,554 from the MAQC-II dataset, with notable overlap in gene expression changes. Pathway analysis using DAVID highlighted MAPK signaling as playing a role during diquat-induced toxicity in both models, with 11 shared transcripts suggesting a conserved molecular response across rodent species. This study aimed to investigate the molecular mechanisms behind diquat-induced toxicity using TAMH cells and identified MAPK signaling pathway as involved. By demonstrating the utility of combining GEO and DAVID for pathway analysis, this study not only highlights potential therapeutic targets for diquat toxicity but also presents a broadly applicable, cost-effective strategy for toxicogenomic research.
- 27 November 2025
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 36 (2) , 241-249
Cross-dataset transcriptomic pathway ranking highlights MAPK signaling in diquat-induced hepatocellular toxicity
Diquat is used in agriculture as an herbicide but poses significant health risks upon exposure. Current treatment for toxic exposures to diquat focuses on supportive care, and there is a need for better understanding of the molecular mechanisms underlying diquat-induced injury in order to develop more targeted antidotes. To this end, TAMH cells were exposed to various concentrations of diquat to determine toxicologically relevant concentrations followed by subsequent transcriptomic analysis. Data mining from the MAQC-II dataset, which was accessed through the Gene Expression Omnibus (GEO) was also leveraged during the gene network analysis. A median lethal concentration (LC50) for diquat in the TAMH line was determined to be 18 μM, with significant cell death observed at 9 hours. Microarray data identified 3,578 significantly altered transcripts in the TAMH model and 6,554 from the MAQC-II dataset, with notable overlap in gene expression changes. Pathway analysis using DAVID highlighted MAPK signaling as playing a role during diquat-induced toxicity in both models, with 11 shared transcripts suggesting a conserved molecular response across rodent species. This study aimed to investigate the molecular mechanisms behind diquat-induced toxicity using TAMH cells and identified MAPK signaling pathway as involved. By demonstrating the utility of combining GEO and DAVID for pathway analysis, this study not only highlights potential therapeutic targets for diquat toxicity but also presents a broadly applicable, cost-effective strategy for toxicogenomic research.
- Open Access
- 6 October 2023
- Published by IntechOpen
Leveraging a hypothesis-generating transcriptomics approach to elucidate molecular pathways that contribute to the biologic effects of quercetin in the liver
Quercetin is a relatively ubiquitous natural product with reported antioxidant, anti-inflammatory, antiviral, and anticarcinogenic properties. Using a bioinformatics approach, differential gene expression analysis was utilized to evaluate quercetins potential to protect and promote hepatocellular health through mining of the Gene Expression Omnibus (GEO) and subsequent analysis using the Database for Annotation and Visualization and Integrated Discovery (DAVID). The publicly available microarray datasets GSE4259 and GSE72081 were analyzed to compare the effect of quercetin on two different liver-based model systems to generate a robust set of differentially expressed genes impacted by quercetin exposure. Results from these analyses identified differentially expressed genes related to calcium signaling and signal transduction pathways to be the most significantly altered. A comprehensive literature review following the transcriptome analysis revealed that quercetin-induced gene expression changes in cell membrane receptors (specifically, voltage gated calcium channels NS integrins) share a common direct signaling pathway through extracellular signal-regulated kinase (ERK). Thus, the results from this bioinformatics study identified potential biomarkers related to quercetins effects on hepatocellular health. Based on quercetins ubiquitous use and good safety profile, future laboratory studies can be directed at validating the observed transcriptional changes on protein expression and the likelihood for hepatoprotection.
- 6 October 2023
- Published by IntechOpen
Open AccessLeveraging a hypothesis-generating transcriptomics approach to elucidate molecular pathways that contribute to the biologic effects of quercetin in the liver
Quercetin is a relatively ubiquitous natural product with reported antioxidant, anti-inflammatory, antiviral, and anticarcinogenic properties. Using a bioinformatics approach, differential gene expression analysis was utilized to evaluate quercetins potential to protect and promote hepatocellular health through mining of the Gene Expression Omnibus (GEO) and subsequent analysis using the Database for Annotation and Visualization and Integrated Discovery (DAVID). The publicly available microarray datasets GSE4259 and GSE72081 were analyzed to compare the effect of quercetin on two different liver-based model systems to generate a robust set of differentially expressed genes impacted by quercetin exposure. Results from these analyses identified differentially expressed genes related to calcium signaling and signal transduction pathways to be the most significantly altered. A comprehensive literature review following the transcriptome analysis revealed that quercetin-induced gene expression changes in cell membrane receptors (specifically, voltage gated calcium channels NS integrins) share a common direct signaling pathway through extracellular signal-regulated kinase (ERK). Thus, the results from this bioinformatics study identified potential biomarkers related to quercetins effects on hepatocellular health. Based on quercetins ubiquitous use and good safety profile, future laboratory studies can be directed at validating the observed transcriptional changes on protein expression and the likelihood for hepatoprotection.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 257
Eugenol Protects Against Diclofenac-Induced Hepatocellular Injury in an In Vitro Mouse Model
ID 14907 Poster Board 257 Background: Eugenol is a simple and widely available hydrocarbon derivative primarily found in cloves, as well as other natural sources like cinnamon and nutmeg. Its phenolic structure suggests that eugenol has the ability to exhibit antioxidant activity. The literature also suggests that eugenol may possess anti-inflammatory properties. The goal of this project was to investigate whether eugenol was capable of protecting against diclofenac-induced hepatocellular injury. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID) has been reported to elevate serum aminotransferase levels, and in some cases may cause serious liver injury. Methods: The toxicity of eugenol and diclofenac were measured by determining a median lethal dose (LC50) in an in vitro mouse liver model (TAMH; transforming growth factor-α transgenic mouse hepatocytes). LC50 values were determined using probit regression analysis in the SPss statistical tool package. TAMH cells were then exposed to a low (non-toxic) dose of eugenol (0.05 mg/mL) for varying pretreatment times before being exposed to a toxic dose of diclofenac (0.70 mg/mL) over a 24-hour period. Cell viabilities were measured following each eugenol/diclofenac treatment condition using a resazurin-based assay. Results: The LC50 values for eugenol and diclofenac were experimentally determined to be 0.14 and 0.57 mg/mL, respectively. An increase in cell viability (cytoprotective effect against diclofenac-induced toxicity) was directly correlated to eugenol pretreatment time. In fact, a five-day eugenol pretreatment resulted in an approximate 3-fold increase in the LC50 of diclofenac alone Conclusions: Relatively long-term eugenol exposure displayed hepatoprotective properties against diclofenac-induced injury. These findings suggest that eugenol may have utility as a dietary supplement capable of protecting the liver against toxic insult. In addition, eugenol might even improve therapeutic outcomes while simultaneously lowering the toxicity risk if combined with diclofenac. Future work is underway to not only explore mechanisms associated with eugenol’s cytoprotective ability against diclofenac-induced toxicity, but also to investigate a potentially synergistic relationship between eugenol and diclofenac related to cyclooxygenase (COX) inhibition. Funding Information: This work was supported by the Pacific University Research Incentive Grant Program and an ASPET Summer Undergraduate Research Fellow (SURF) Institutional Award.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 257
Open AccessEugenol Protects Against Diclofenac-Induced Hepatocellular Injury in an In Vitro Mouse Model
ID 14907 Poster Board 257 Background: Eugenol is a simple and widely available hydrocarbon derivative primarily found in cloves, as well as other natural sources like cinnamon and nutmeg. Its phenolic structure suggests that eugenol has the ability to exhibit antioxidant activity. The literature also suggests that eugenol may possess anti-inflammatory properties. The goal of this project was to investigate whether eugenol was capable of protecting against diclofenac-induced hepatocellular injury. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID) has been reported to elevate serum aminotransferase levels, and in some cases may cause serious liver injury. Methods: The toxicity of eugenol and diclofenac were measured by determining a median lethal dose (LC50) in an in vitro mouse liver model (TAMH; transforming growth factor-α transgenic mouse hepatocytes). LC50 values were determined using probit regression analysis in the SPss statistical tool package. TAMH cells were then exposed to a low (non-toxic) dose of eugenol (0.05 mg/mL) for varying pretreatment times before being exposed to a toxic dose of diclofenac (0.70 mg/mL) over a 24-hour period. Cell viabilities were measured following each eugenol/diclofenac treatment condition using a resazurin-based assay. Results: The LC50 values for eugenol and diclofenac were experimentally determined to be 0.14 and 0.57 mg/mL, respectively. An increase in cell viability (cytoprotective effect against diclofenac-induced toxicity) was directly correlated to eugenol pretreatment time. In fact, a five-day eugenol pretreatment resulted in an approximate 3-fold increase in the LC50 of diclofenac alone Conclusions: Relatively long-term eugenol exposure displayed hepatoprotective properties against diclofenac-induced injury. These findings suggest that eugenol may have utility as a dietary supplement capable of protecting the liver against toxic insult. In addition, eugenol might even improve therapeutic outcomes while simultaneously lowering the toxicity risk if combined with diclofenac. Future work is underway to not only explore mechanisms associated with eugenol’s cytoprotective ability against diclofenac-induced toxicity, but also to investigate a potentially synergistic relationship between eugenol and diclofenac related to cyclooxygenase (COX) inhibition. Funding Information: This work was supported by the Pacific University Research Incentive Grant Program and an ASPET Summer Undergraduate Research Fellow (SURF) Institutional Award.
- Open Access
- 28 January 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (2) , 267
Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise
Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans worldwide. Because a vaccine is not available and the currently small number of existing drugs are less than ideal due to lack of specificity and emerging drug resistance, the need for new therapeutic strategies is urgent. Natural products and their derivatives are being used and explored as therapeutics and interest in developing such products as antileishmanials is high. The enzyme arginase, the first enzyme of the polyamine biosynthetic pathway in Leishmania, has emerged as a potential therapeutic target. The flavonols quercetin and fisetin, green tea flavanols such as catechin (C), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin-3-gallate (EGCG), and cinnamic acid derivates such as caffeic acid inhibit the leishmanial enzyme and modulate the host’s immune response toward parasite defense while showing little toxicity to the host. Quercetin, EGCG, gallic acid, caffeic acid, and rosmarinic acid have proven to be effective against Leishmania in rodent infectivity studies. Here, we review research on these natural products with a focus on their promise for the development of treatment strategies as well as unique structural and pharmacokinetic/pharmacodynamic features of the most promising agents.
- 28 January 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (2) , 267
Open AccessNatural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise
Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans worldwide. Because a vaccine is not available and the currently small number of existing drugs are less than ideal due to lack of specificity and emerging drug resistance, the need for new therapeutic strategies is urgent. Natural products and their derivatives are being used and explored as therapeutics and interest in developing such products as antileishmanials is high. The enzyme arginase, the first enzyme of the polyamine biosynthetic pathway in Leishmania, has emerged as a potential therapeutic target. The flavonols quercetin and fisetin, green tea flavanols such as catechin (C), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin-3-gallate (EGCG), and cinnamic acid derivates such as caffeic acid inhibit the leishmanial enzyme and modulate the host’s immune response toward parasite defense while showing little toxicity to the host. Quercetin, EGCG, gallic acid, caffeic acid, and rosmarinic acid have proven to be effective against Leishmania in rodent infectivity studies. Here, we review research on these natural products with a focus on their promise for the development of treatment strategies as well as unique structural and pharmacokinetic/pharmacodynamic features of the most promising agents.
- Open Access
A Template-Based Approach for Guiding and Refining the Development of Cinnamon-Based Phenylpropanoids as Drugs
Background: Structure-activity relationships describe the relationship between chemical structure and biologic activity and are capable of informing deliberate structural modifications to a molecule in order enhance drug properties. Methods: Here, we present a subtle, yet unique twist on structure-activity relationships in which a collective biologic activity was measured among five cinnamon constituents with a shared phenylpropanoid template (cinnamic acid, cinnamaldehyde, chlorogenic acid, caffeic acid, and ferulic acid). This template-based approach utilized publicly available transcriptomic data through the Gene Expression Omnibus (GEO) to identify a fundamental biologic effect; in essence, a phenylpropanoid template effect. Results: The recurrent identification of cytokine-cytokine receptor interaction and neuroactive ligand receptor pathways in each individual treatment condition strongly supports the fact that changes in gene expression within these pathways is a hallmark of the phenylpropanoid template. With a template effect identified, future structural modifications can be performed in order to overcome pharmacokinetic barriers to clinical use (i.e., traditional structure-activity relationship experiments). Moreover, these modifications can be implemented with a high degree of confidence knowing that a consistent and robust template effect is likely to persist. Conclusion: We believe this template-based approach offers researchers an attractive and cost-effective means for evaluating multicomponent natural products during drug development.
Open AccessA Template-Based Approach for Guiding and Refining the Development of Cinnamon-Based Phenylpropanoids as Drugs
Background: Structure-activity relationships describe the relationship between chemical structure and biologic activity and are capable of informing deliberate structural modifications to a molecule in order enhance drug properties. Methods: Here, we present a subtle, yet unique twist on structure-activity relationships in which a collective biologic activity was measured among five cinnamon constituents with a shared phenylpropanoid template (cinnamic acid, cinnamaldehyde, chlorogenic acid, caffeic acid, and ferulic acid). This template-based approach utilized publicly available transcriptomic data through the Gene Expression Omnibus (GEO) to identify a fundamental biologic effect; in essence, a phenylpropanoid template effect. Results: The recurrent identification of cytokine-cytokine receptor interaction and neuroactive ligand receptor pathways in each individual treatment condition strongly supports the fact that changes in gene expression within these pathways is a hallmark of the phenylpropanoid template. With a template effect identified, future structural modifications can be performed in order to overcome pharmacokinetic barriers to clinical use (i.e., traditional structure-activity relationship experiments). Moreover, these modifications can be implemented with a high degree of confidence knowing that a consistent and robust template effect is likely to persist. Conclusion: We believe this template-based approach offers researchers an attractive and cost-effective means for evaluating multicomponent natural products during drug development.
- Open Access
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 672.6
Structure‐Toxicity Relationships of Trans‐Cinnamic Aldehyde and Its Substituted Analogs
Objective: Trans‐cinnamic aldehyde (CA) is a compound found in cinnamon and has promising potential as an agent for smoking cessation therapy. Current pharmaceutical options to treat nicotine addiction are only moderately effective and new approaches are needed. In this study, we aim to explore the hepatotoxicity profiles of CA and its structurally‐related analogs as one step in a more‐extensive evaluation of these agents to treat nicotine addiction. Methods: Mouse hepatocytes were exposed to varying concentrations of CA or its structurally‐related analogs and toxicity was measured by determining median lethal dose (LC50) values. Stock solutions for all compounds were prepared in DMSO and proper vehicle controls were performed for all experiments. Cells were treated with either CA or one of eight analogs: α‐bromocinnamaldehyde (Br‐CA), α‐chlorocinnamaldehyde (Cl‐CA), 3‐phenylpropionaldehyde (sat‐CA), α‐methylcinnamaldehyde (Me‐CA), 2‐nitrocinnamaldehyde (N‐CA), 2‐trifluoromethylcinnamadehyde (CF3‐CA), 2,6‐difluorocinnamaldehyde (F‐CA), and 2‐methylcinnamaldehyde (2‐Me‐CA). After the LC50 determinations were completed, two different luminescence‐based assays were performed to assess reactive oxygen species production and glutathione (GSH) depletion during exposure to CA and its analogs. A cutoff of p < 0.05 was used to determine significance by means of one‐way analysis of variance (ANOVA) with post‐hoc Least Significant Difference (LSD) tests. Results: Significant differences in LC50 values were observed across the tested compounds indicating minor structural changes to the structure of CA can have profound toxicologic effects. CA analogs modified to contain electron‐withdrawing groups, as well as CA itself, were generally more toxic (lower LC50 values) than those that did not contain electron‐withdrawing groups. Furthermore, this toxicity was associated with significantly greater reactive oxygen species production and GSH depletion compared to the other CA analogs at equi‐toxic doses. Conclusion: These results indicate analogs that contain electron‐withdrawing groups share a similar or inferior toxicity profile compared to CA significantly impacting the generation of reactive oxygen species and GSH depletion. However, this toxicity profile is unique for other CA analogs that do not contain electron‐withdrawing groups, which appear to propagate toxicity through alternative cell death mechanisms. Information generated from this study will help to inform future pharmacologic studies in animal and human models as these agents are further evaluated as potential aids for smoking cessation therapy. Support or Funding Information This work was supported by the Pacific University Research Incentive Grant Program This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 672.6
Open AccessStructure‐Toxicity Relationships of Trans‐Cinnamic Aldehyde and Its Substituted Analogs
Objective: Trans‐cinnamic aldehyde (CA) is a compound found in cinnamon and has promising potential as an agent for smoking cessation therapy. Current pharmaceutical options to treat nicotine addiction are only moderately effective and new approaches are needed. In this study, we aim to explore the hepatotoxicity profiles of CA and its structurally‐related analogs as one step in a more‐extensive evaluation of these agents to treat nicotine addiction. Methods: Mouse hepatocytes were exposed to varying concentrations of CA or its structurally‐related analogs and toxicity was measured by determining median lethal dose (LC50) values. Stock solutions for all compounds were prepared in DMSO and proper vehicle controls were performed for all experiments. Cells were treated with either CA or one of eight analogs: α‐bromocinnamaldehyde (Br‐CA), α‐chlorocinnamaldehyde (Cl‐CA), 3‐phenylpropionaldehyde (sat‐CA), α‐methylcinnamaldehyde (Me‐CA), 2‐nitrocinnamaldehyde (N‐CA), 2‐trifluoromethylcinnamadehyde (CF3‐CA), 2,6‐difluorocinnamaldehyde (F‐CA), and 2‐methylcinnamaldehyde (2‐Me‐CA). After the LC50 determinations were completed, two different luminescence‐based assays were performed to assess reactive oxygen species production and glutathione (GSH) depletion during exposure to CA and its analogs. A cutoff of p < 0.05 was used to determine significance by means of one‐way analysis of variance (ANOVA) with post‐hoc Least Significant Difference (LSD) tests. Results: Significant differences in LC50 values were observed across the tested compounds indicating minor structural changes to the structure of CA can have profound toxicologic effects. CA analogs modified to contain electron‐withdrawing groups, as well as CA itself, were generally more toxic (lower LC50 values) than those that did not contain electron‐withdrawing groups. Furthermore, this toxicity was associated with significantly greater reactive oxygen species production and GSH depletion compared to the other CA analogs at equi‐toxic doses. Conclusion: These results indicate analogs that contain electron‐withdrawing groups share a similar or inferior toxicity profile compared to CA significantly impacting the generation of reactive oxygen species and GSH depletion. However, this toxicity profile is unique for other CA analogs that do not contain electron‐withdrawing groups, which appear to propagate toxicity through alternative cell death mechanisms. Information generated from this study will help to inform future pharmacologic studies in animal and human models as these agents are further evaluated as potential aids for smoking cessation therapy. Support or Funding Information This work was supported by the Pacific University Research Incentive Grant Program This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- Open Access
- 1 January 2019
- Published by SAGE Publications in Gene Regulation and Systems Biology
- Vol. 13
Model-based Evaluation of Gene Expression Changes in Response to Leishmania Infection
Since the development of high-density microarray technology in the late 1990s, global host gene expression changes in response to various stimuli have been extensively studied. More than a dozen peer-reviewed publications have investigated the effect of Leishmania infection in various models since 2001. This review covers the transcriptional changes in macrophage models induced by various Leishmania species and summarizes the resulting impact these studies have on our understanding of the host response to leishmaniasis in vitro. Characterization of the similarities and differences between various model systems will not only further our understanding of Leishmania-induced changes to macrophage gene expression but also identify potential therapeutic targets in the future.
- 1 January 2019
- Published by SAGE Publications in Gene Regulation and Systems Biology
- Vol. 13
Open AccessModel-based Evaluation of Gene Expression Changes in Response to Leishmania Infection
Since the development of high-density microarray technology in the late 1990s, global host gene expression changes in response to various stimuli have been extensively studied. More than a dozen peer-reviewed publications have investigated the effect of Leishmania infection in various models since 2001. This review covers the transcriptional changes in macrophage models induced by various Leishmania species and summarizes the resulting impact these studies have on our understanding of the host response to leishmaniasis in vitro. Characterization of the similarities and differences between various model systems will not only further our understanding of Leishmania-induced changes to macrophage gene expression but also identify potential therapeutic targets in the future.
- 1 November 2017
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 277, 129-136
Polyphenols reported to shift APAP-induced changes in MAPK signaling and toxicity outcomes
- 1 November 2017
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 277, 129-136
Polyphenols reported to shift APAP-induced changes in MAPK signaling and toxicity outcomes